img1

Enhancing
immune response
to improve
cancer survival

Sonnet Platform

Sonnet is utilizing a platform approach to develop immuno-oncology therapeutics featuring a proprietary fully human “Albumin Binding Domain” (ABD) capable of linking 1-2 different therapeutic targets.  As an example, an interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model.

The Sonnet platform de-risks the use of interleukins by greatly extending their in vivo half-life, while also improving their specificity to tumor tissue. We believe this therapeutic approach in combination with checkpoint inhibitors has significant therapeutic potential.

2

Platform

Sonnet’s discovery platform enables modular plug-and-play development of therapies against a varierty of targets…

Pipeline

Sonnet is advancing multiple immuno-oncology candidates into CMC development…

progress

Progress

Sonnet BioTherapeutics has established proof of preclinical concept with our albumin binding ScFv with up to 10x increases in serum half-life and improved tumor penetration…

adminHome